AXL hyperactivation and evidence for EMT were previously reported in multiple in vitro and in vivo EGFR-mutant lung cancer models with acquired resistance to erlotinib independent of the EGFR T790M alteration and MET activation [32]. This evidence concerns the gene AXL and lung carcinoma.